Compare CHEF & VERA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CHEF | VERA |
|---|---|---|
| Founded | 1985 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Food Distributors | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.3B | 3.0B |
| IPO Year | 2011 | 2021 |
| Metric | CHEF | VERA |
|---|---|---|
| Price | $98.56 | $42.92 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 6 | 10 |
| Target Price | $76.33 | ★ $81.30 |
| AVG Volume (30 Days) | 488.3K | ★ 2.4M |
| Earning Date | 04-29-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 27.27 | N/A |
| EPS | ★ 0.40 | N/A |
| Revenue | ★ $1,301,520,000.00 | N/A |
| Revenue This Year | $8.66 | N/A |
| Revenue Next Year | $7.83 | $472.48 |
| P/E Ratio | $243.74 | ★ N/A |
| Revenue Growth | ★ 9.11 | N/A |
| 52 Week Low | $53.24 | $19.07 |
| 52 Week High | $99.47 | $56.05 |
| Indicator | CHEF | VERA |
|---|---|---|
| Relative Strength Index (RSI) | 68.43 | 63.28 |
| Support Level | $57.47 | $37.34 |
| Resistance Level | N/A | $43.30 |
| Average True Range (ATR) | 3.03 | 2.73 |
| MACD | -0.39 | 0.06 |
| Stochastic Oscillator | 92.17 | 75.89 |
The Chefs' Warehouse Inc is a specialty food distributor in metropolitan areas across the United States, the Middle East and Canada. The company's product portfolio is comprised of imported and local specialty food products such as cheese, cooking oils, chocolates, dried food, baking products, meats, and other food products. It operates via one reporting segment called Food Product Distribution. Operations are concentrated on the east, midwest, and west coasts of the U.S. The company provides service to restaurants, clubs, hotels, caterers, schools, bakeries, casinos, and specialty food stores.
Vera Therapeutics Inc is a clinical stage biotechnology company. It is focused on developing and commercializing transformative treatments for patients with serious immunological diseases. The company's product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection once weekly that blocks both B lymphocyte stimulator and a proliferation-inducing ligand, which stimulate B cells and plasma cells to produce autoantibodies contributing to certain autoimmune diseases.